A vascular graft, also known as a vascular bypass, is a surgical operation that redirects blood from one area of normal blood flow to another reasonably normal area. Different vascular grafts are available depending on the indication and raw materials used to suit the host tissue. Hemodialysis vascular access and endovascular aneurysm and thoracic aneurysm repair are both done with vascular grafts.

The vascular grafts market is expected to grow at a CAGR of 7.3 percent from USD 2.67 billion in 2017 to USD 3.80 billion in 2022. The high frequency of abdominal aneurysms, the growing geriatric population, and the rising prevalence of smoking and other risk factors that induce aneurysm are all driving this market's expansion.

Get PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=179457001

"The polyester grafts segment will hold the greatest market share by raw material over the projection period."
Because of its widespread use in vascular grafts and its extended lifespan, polyester grafts are likely to command the biggest market share. During the projection period, this segment is also expected to have the greatest CAGR.

"By indication, the endovascular aneurysm repair sector will grow at the fastest rate and hold the largest market share."
The expanding acceptance of endovascular aneurysm repair surgical techniques, increasing preference for minimally invasive surgical procedures over open surgeries, and the growing geriatric population are all driving this segment's rise.

"During the projected period, the hospitals segment is expected to develop at the fastest CAGR."
During the anticipated period, the hospitals category is expected to develop at the fastest CAGR. The strong growth of this category can be attributable to reasons such as the increasing number of minimally invasive surgical procedures performed in hospitals and cardiac centres, as well as attractive reimbursement scenarios in most industrialised nations.

"During the projected period, APAC will lead the worldwide vascular grafts market."
The increased prevalence of CKD, healthcare reforms, government initiatives and investments, and rapid growth in the senior population are all contributing to the Asia Pacific market's expanding growth. In addition, emerging markets such as Australia, Singapore, Japan, and China provide various potential prospects for vascular grafts market participants because to an ageing population and an increase in end-stage renal disease.

Get a Sample of Vascular Graft Market

https://www.marketsandmarkets.com/requestsampleNew.asp?id=179457001

Product failures and recalls require restraint.
Patients can suffer serious or even fatal consequences as a result of product failures. Several firms' products have been recalled from the market over the years owing to product faults or other difficulties. End-user perceptions of graft safety may be harmed by market trends, which may affect their acceptance in treatment methods.

Emerging market opportunity
Emerging markets including Australia, Singapore, Japan, and China provide considerable growth potential for vascular grafts manufacturers. According to the NCBI, 985 out of 999 patients who received EVAR in Japan between 2007 and 2015 were above 50 years old. Because Japan has the highest proportion of elderly people, a growth in this population segment will lead to an increase in aortic aneurysms. According to Ministry of Internal Affairs and Communication figures from 2014, 33.0% of the Japanese population is above the age of 60. By 2050, 40 percent of Japan's population is predicted to be over 65.

Because of their relatively lax regulatory regulations and the rising prevalence of aneurysms, these markets are projected to grow rapidly in the next years. Major players have responded by expanding their geographic presence into emerging markets. Medtronic Inc. (US) inaugurated its Asia Pacific regional headquarters in Singapore in May 2016 to assist and strengthen its operations in 80 locations throughout Asia Pacific.

Key Market Players

Medtronic (Ireland), B. Braun (Germany), Endologix (US), Terumo (Japan), C. R. Bard (US)